Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 8 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $1,977,143, and 5 were calls, valued at $222,954.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $135.0 for Novo Nordisk over the last 3 months.
Volume & Open Interest Development
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Novo Nordisk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Novo Nordisk's substantial trades, within a strike price spectrum from $85.0 to $135.0 over the preceding 30 days.
Novo Nordisk 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
| NVO | PUT | TRADE | NEUTRAL | 09/19/25 | $47.95 | $45.9 | $47.0 | $135.00 | $1.8M | 1 | 400 |
| NVO | CALL | TRADE | NEUTRAL | 01/15/27 | $22.35 | $21.45 | $21.85 | $85.00 | $80.8K | 386 | 37 |
| NVO | PUT | TRADE | BULLISH | 01/10/25 | $28.25 | $26.65 | $27.15 | $115.00 | $65.1K | 0 | 24 |
| NVO | CALL | TRADE | BEARISH | 01/15/27 | $12.85 | $12.1 | $12.35 | $110.00 | $45.6K | 642 | 0 |
| NVO | CALL | SWEEP | BULLISH | 01/17/25 | $4.6 | $4.5 | $4.6 | $85.00 | $41.3K | 1.4K | 107 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
In light of the recent options history for Novo Nordisk, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Novo Nordisk's Current Market Status
- Trading volume stands at 354,286, with NVO's price up by 0.03%, positioned at $87.68.
- RSI indicators show the stock to be may be oversold.
- Earnings announcement expected in 40 days.
What Analysts Are Saying About Novo Nordisk
1 market experts have recently issued ratings for this stock, with a consensus target price of $105.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.* Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Novo Nordisk with a target price of $105.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
金融巨頭對諾和諾德採取了明顯的看漲舉動。我們對諾和諾德（紐約證券交易所代碼：NVO）期權歷史的分析顯示了8筆不尋常的交易。
深入研究細節，我們發現50％的交易者看漲，而25％的交易者表現出看跌趨勢。在我們發現的所有交易中，有3筆是看跌期權，價值爲1,977,143美元，5筆是看漲期權，價值222,954美元。
預測的價格區間
考慮到這些合約的交易量和未平倉合約，在過去的3個月中，鯨魚似乎一直將Novo Nordisk的價格定在85.0美元至135.0美元之間。
成交量和未平倉合約發展
評估交易量和未平倉合約是期權交易的戰略步驟。這些指標揭示了Novo Nordisk在指定行使價下期權的流動性和投資者對Novo Nordisk期權的興趣。即將發佈的數據可視化了與諾和諾德的大量交易相關的看漲期權和未平倉合約的波動，在過去30天內，行使價範圍從85.0美元到135.0美元不等。
Novo Nordisk 30 天期權交易量和利息快照
觀察到的最大期權交易：
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|
NVO | PUT | TRADE | NEUTRAL | 09/19/25 | $47.95 | $45.9 | $47.0 | $135.00 | $1.8M | 1 | 400 |
NVO | CALL | TRADE | NEUTRAL | 01/15/27 | $22.35 | $21.45 | $21.85 | $85.00 | $80.8K | 386 | 37 |
NVO | PUT | TRADE | BULLISH | 01/10/25 | $28.25 | $26.65 | $27.15 | $115.00 | $65.1K | 0 | 24 |
NVO | CALL | TRADE | BEARISH | 01/15/27 | $12.85 | $12.1 | $12.35 | $110.00 | $45.6K | 642 | 0 |
NVO | CALL | SWEEP | BULLISH | 01/17/25 | $4.6 | $4.5 | $4.6 | $85.00 | $41.3K | 1.4K | 107 |
關於諾和諾德
Novo Nordisk擁有全球品牌糖尿病治療市場約三分之一的份額，是全球領先的糖尿病護理產品提供商。該公司總部位於丹麥，生產和銷售各種人類和現代胰島素、可注射的糖尿病治療藥物，例如 GLP-1 療法、口服抗糖尿病藥物和肥胖療法。Novo還有一個生物製藥板塊（約佔收入的10％），專門從事血友病和其他疾病的蛋白質療法。
鑑於Novo Nordisk最近的期權歷史，現在應該將重點放在公司本身上。我們的目標是探索其目前的表現。
諾和諾德的當前市場狀況
分析師對諾和諾德的看法
1位市場專家最近發佈了該股的評級，共識目標價爲105.0美元。
在短短 20 天內將 1000 美元變成 1270 美元？
20年專業期權交易員透露了他的單線圖技術，該技術顯示何時買入和賣出。複製他的交易，平均每20天獲利27％。點擊此處查看。* BMO Capital的一位分析師在評估中保持了對諾和諾德跑贏大盤的評級，目標價爲105美元。
期權交易具有更高的風險和潛在的回報。精明的交易者通過不斷自我教育、調整策略、監控多個指標以及密切關注市場走勢來管理這些風險。藉助Benzinga Pro的實時提醒，隨時了解最新的諾和諾德期權交易。
